

# VeriSee DR

## AI-Assisted Diagnostic Software for Diabetic Retinopathy



### All-New Feature : Lesion Detection

### Clinically-proven performance

VeriSee DR has a screening accuracy of 93%<sup>1</sup>, which is comparable to ophthalmologists. It also supports multiple retinal camera brands, such as Topcon, Canon, Crystalvue, Nikon, Nidek, and MiiS.

The software helps healthcare professionals to analyze retinal images for signs of DR and immediately outputs recommendations on referral to ophthalmologists.

## Product Features



**1** The first ophthalmic AI Software as a Medical Device (SaMD) approved by Taiwan FDA



**2** Performance and impacts validated through rigorous clinical trial and real-world studies published in medical journals



**3** Detection of four main DR lesions, including microaneurysms, hemorrhages, soft exudates, and hard exudates



**4** Quick screening and instant analysis for high-risk cases based on the criteria of international classification of DR<sup>2</sup>



**5** Supports integration with hospital information system (HIS) and picture archiving and communication system (PACS)


<sup>1</sup> The above performance is based on the results of a pivotal clinical trial approved by Taiwan FDA

<sup>2</sup> International Clinical Diabetic Retinopathy Disease Severity Scale

\* The product appearance is for reference only.

# Real-Time Detection of DR Lesions

VeriSee DR detects the major lesions comprehensively and shows their corresponding locations. The referral recommendation results can be cross-referenced with the lesion detection results, which can reduce false positive and false negative results.



\* The product appearance is for reference only.

## Product Benefits



### Endocrinologists

- Increase the accuracy and speed of DR screening<sup>3</sup>
- Refer DR patients to ophthalmologists before deteriorating



### Ophthalmologists

- Provide early treatments and achieve better patient outcomes
- Lesion detection function increases image-reading efficiency



### Diabetic Patients

- Obtain effective DR screening
- Receive early diagnosis and treatment

<sup>3</sup> Clinical Impact of VeriSee DR in the Primary Care Setting

Li, Yu-Hsuan, et al. "The clinical influence after implementation of convolutional neural network-based software for diabetic retinopathy detection in the primary care setting." Life 11.3 (2021): 200.

## Recommended Hardware

<b>CPU</b>	Intel® Core™ i7 (must support AVX instruction set)
<b>Graphic Card (Optional)</b>	GPU NVIDIA GEFORCE GTX-1080 (only graphics cards above NVIDIA 6G memory are supported)
<b>Storage</b>	256 GB or above ; best performance 512 GB
<b>RAM</b>	16 GB
<b>OS</b>	Windows 10/11 x64

## Other Details

<b>Input Data</b>	Color fundus image (DICOM, JPG or PNG)
<b>Output Result</b>	Provides referral recommendations and analyzes the image for signs of DR. Results will be displayed in the browser with the option to export report in PDF files.
<b>License Options</b>	- Perpetual licensing - Subscription licensing



If you would like to learn more about VeriSee DR, please contact us at [contact@acer-medical.com](mailto:contact@acer-medical.com) or scan the QR code to visit our site <https://www.acer-medical.com/>